![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Preprint)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
3MB |
![[thumbnail of Supplementary Material]](https://edoc.mdc-berlin.de/style/images/fileicons/other.png) |
Other (Supplementary Material)
26MB |
| Item Type: | Preprint |
|---|---|
| Title: | Oncogenic RAS-pathway activation drives oncofetal reprogramming and creates therapeutic vulnerabilities in juvenile myelomonocytic leukemia |
| Creators Name: | Hartmann, Mark, Schoenung, Maximilian, Rajak, Jovana, Maurer, Valentin, Hai, Ling, Bauer, Katharina, Hakobyan, Mariam, Staeble, Sina, Langstein, Jens, Jardine, Laura, Roelz, Roland, Bohler, Sheila, Khabirova, Eleonora, Maag, Abdul-Habib, Vonficht, Dominik, Lebrecht, Dirk, Bernt, Katrin M., Tan, Kai, Chen, Changya, Alikarami, Fatemeh, Boch, Tobias, Flore, Viktoria, Lutsik, Pavlo, Milsom, Michael D., Raffel, Simon, Buske, Christian, Haas, Simon, Haniffa, Muzlifah, Mallm, Jan-Philipp, Behjati, Sam, Bonder, Marc-Jan, Froehling, Stefan, Niemeyer, Charlotte M., Hey, Joschka, Flotho, Christian, Plass, Christoph, Erlacher, Miriam, Schlesner, Matthias and Lipka, Daniel B. |
| Abstract: | Aberrant fetal gene expression facilitates tumor-specific cellular plasticity by hijacking molecular programs of embryogenesis. Persistent fetal gene signatures in childhood malignancies are typically explained by their prenatal origins. In contrast, reactivation of fetal gene expression is considered a consequence of oncofetal reprogramming (OFR) in adult malignancies and is associated with aggressive disease. To date, OFR has not been described in the context of childhood malignancies. Here, we performed a comprehensive multi-layered molecular characterization of juvenile myelomonocytic leukemia (JMML) and identified OFR as a hallmark of aggressive JMML. We observed that hematopoietic stem cells (HSCs) aberrantly express mixed developmental programs in JMML. Expression of fetal gene signatures combined with a postnatal epigenetic landscape suggested OFR, which was validated in a JMML mouse model, demonstrating that postnatal activation of RAS signaling is sufficient to induce fetal gene signatures. Integrative analysis identified the fetal HSC maturation marker CD52 as a novel therapeutic target for aggressive JMML. Anti-CD52 treatment depleted human JMML HSCs and disrupted disease propagation in vivo. In summary, this study implicates OFR, defined as postnatal acquisition of fetal transcription signatures, in the pathobiology of a childhood malignancy. We provide evidence for the direct involvement of oncogenic RAS signaling in OFR. Finally, we demonstrate how OFR can be leveraged for the development of novel treatment strategies. |
| Keywords: | Animals, Mice |
| Source: | bioRxiv |
| Publisher: | Cold Spring Harbor Laboratory Press |
| Article Number: | 2023.10.27.563754 |
| Date: | 1 November 2023 |
| Official Publication: | https://doi.org/10.1101/2023.10.27.563754 |
| Related to: |
Repository Staff Only: item control page
